Home > News > SJTU Team Found Potential Therapeutic Target for Eradication of Leukemic Initiating Cells

SJTU Team Found Potential Therapeutic Target for Eradication of Leukemic Initiating Cells

April 19, 2018      Author: Zheng Junke

With the generous support from Professor Chen Guoqiang, Professor Zheng Junke is the corresponding author of the paper. Dr. Zhang Yangping, Dr. Xia Fangzhen, Dr. Liu Xiaoye and Associate Professor Yu Zhuo are the first authors. The article marks another breakthrough since Professor Chen Guoqiang and Zheng Kejun revealed distinctive functions of immunosuppressive molecules on Leukemia-initiating cells (LICs) in the Journal of Clinical Investigation in 2017.

Leukemia-initiating cells (LICs) are responsible for the initiation, development, and relapse of leukemia. The identification of novel therapeutic LIC targets is critical to curing leukemia. In this report, we reveal that junctional adhesion molecule 3 (JAM3) is highly enriched in both mouse and human LICs. Leukemogenesis is almost completely abrogated upon Jam3 deletion during serial transplantations in an MLL-AF9-induced murine acute myeloid leukemia model. In contrast, Jam3 deletion does not affect the functions of mouse hematopoietic stem cells. Moreover, knockdown of JAM3 leads to a dramatic decrease in the proliferation of both human leukemia cell lines and primary LICs. JAM3 directly associates with LRP5 to activate the downstream PDK1/AKT pathway, followed by the downregulation of GSK3β and activation of β-catenin/CCND1 signaling, to maintain the self-renewal ability and cell cycle entry of LICs. Thus, JAM3 may serve as a functional LIC marker and play an important role in the maintenance of LIC stemness through unexpected LRP5/PDK1/AKT/GSK3β/β-catenin/CCND1 signaling pathways but not via its canonical role in cell junctions and migration. JAM3 may be an ideal without influencing normal hematopoiesis.

Link of the paper:

Translated by Liu Yixuan   Reviewed by Wang Bingyu